MAT certification refers to the credentials and regulatory approvals that allow healthcare practitioners to prescribe addiction medications, or that authorize treatment facilities to dispense them. MAT stands for medication-assisted treatment, a approach to opioid use disorder that combines specific medications with counseling and behavioral therapy. The certification landscape changed significantly in 2023 when federal law eliminated the longstanding “X-waiver” system, making it easier for practitioners to prescribe one of the key medications used in treatment.
The Three Medications in MAT
Three drugs form the backbone of medication-assisted treatment, each working differently in the body. Methadone fully activates the same brain receptors that opioids target, reducing cravings and withdrawal without producing a high at proper doses. Buprenorphine partially activates those receptors, offering a ceiling effect that makes overdose less likely. It’s sometimes combined with naloxone (sold under brand names like Suboxone) to discourage misuse. Naltrexone takes the opposite approach entirely: it blocks opioid receptors so that even if someone uses opioids, the effects are blunted.
These medications carry different levels of federal regulation. Methadone is classified as a Schedule II controlled substance, the most tightly restricted category for drugs with accepted medical use. Buprenorphine falls under Schedule III, a less restrictive tier. Naltrexone is not a controlled substance at all, which means prescribing it requires no special certification beyond a standard medical license.
What Changed in 2023
For over two decades, prescribing buprenorphine for opioid use disorder required a special federal waiver. Under the Drug Addiction Treatment Act of 2000, practitioners had to submit a “Notice of Intent” to SAMHSA, complete extra training hours, and receive a separate prescribing number (the X-waiver). Strict patient caps limited how many people a single practitioner could treat, starting at just 30 patients in the first year.
The Consolidated Appropriations Act of 2023 swept all of that away. SAMHSA no longer accepts waiver applications, and any practitioner with a current DEA registration that includes Schedule III authority can now prescribe buprenorphine for opioid use disorder, as long as state law permits it. There are no longer any patient caps. A practitioner can treat as many patients as they can reasonably support. Prescriptions now require only a standard DEA registration number, not a special waiver number.
Current Training Requirements
The 2023 law replaced the waiver system with a new training mandate called the MATE Act (Medications for Addiction Treatment Education). Starting June 27, 2023, anyone applying for a new DEA registration or renewing an existing one must meet at least one of three conditions:
- Eight hours of training on opioid or other substance use disorders from approved organizations
- Board certification in addiction medicine or addiction psychiatry from the American Board of Medical Specialties, the American Board of Addiction Medicine, or the American Osteopathic Association
- Recent graduation (within the past five years) from an accredited medical, physician assistant, or advanced practice nursing school whose curriculum included at least eight hours of substance use disorder education
This requirement applies to all DEA-registered practitioners except veterinarians. That includes physicians, physician assistants, nurse practitioners, and other mid-level providers authorized by their state to prescribe controlled medications in Schedules II through V. The training isn’t specific to buprenorphine prescribing; it’s now a baseline requirement for anyone who wants to prescribe any controlled substance.
Certification for Treatment Programs
While individual practitioners can now prescribe buprenorphine from a regular office setting, methadone is a different story. Methadone for opioid use disorder can only be dispensed through federally regulated opioid treatment programs (OTPs), and these facilities go through a multi-step certification process.
An OTP must be certified by SAMHSA, accredited by a SAMHSA-approved accrediting body, licensed by the state where it operates, and registered with the DEA. New programs can apply for provisional certification using SAMHSA’s Form SMA-162, which grants temporary approval for up to one year while the program works toward full accreditation. SAMHSA will not grant even provisional certification without state and DEA approvals already in place.
Once a provisionally certified program achieves accreditation, it must apply to SAMHSA for full certification through a renewal application. SAMHSA compliance officers review all documentation to confirm the program meets federal standards. After that, OTPs renew their certification either annually or every three years, depending on the accreditation timeframe they were awarded. Patients receiving methadone through these programs typically report to the facility daily or near-daily to receive their dose, though take-home privileges can expand over time.
State Rules Can Be Stricter
Federal law sets the floor, not the ceiling. A 2022 analysis found that at least 14 states imposed requirements on buprenorphine prescribers that went beyond federal minimums. Seven states still required waiver-specific training through their own regulations, and ten states required practitioners to provide or arrange counseling and ancillary services as a condition of prescribing.
These extra requirements varied by practitioner type. Kentucky, for example, required additional waiver training for physicians, physician assistants, and advanced practice nurses alike. States like Arkansas, Indiana, Ohio, and West Virginia imposed counseling requirements on physician assistants and nurse practitioners but not on physicians. In some states, the stricter rules applied only in specific contexts, such as office-based treatment practices, facilities treating Medicaid patients, or workers’ compensation cases. If you’re a practitioner, checking your state medical board’s current regulations is essential, because your state may layer additional requirements on top of the federal framework.
How Retention Rates Reflect Program Quality
One way to gauge whether a certified MAT program is working is patient retention, meaning how many people stay in treatment over time. A 2023 analysis of opioid treatment programs found that the median program kept 61.2% of patients at 30 days, 41.5% at 90 days, and just 27.5% at 180 days. Those numbers highlight a real challenge: even in certified, regulated programs, keeping patients engaged long enough to benefit is difficult. Staying on methadone or buprenorphine is associated with reduced overdose and death, so retention isn’t just an administrative metric. It’s directly tied to survival.
For patients or families evaluating a program, these benchmarks offer useful context. A program that retains well above 27.5% of its patients at six months is outperforming the national median. Asking about retention rates, along with confirming state licensure and SAMHSA certification, can help you distinguish effective programs from those that simply meet minimum standards.